Truist raised the firm’s price target on Synovus to $38 from $31 and keeps a Buy rating on the shares after the company’s updated Q4 and 2024 guidance. The analyst is citing expectations of higher net interest margin and fee income, the announced securities portfolio restructuring and recurring benefits from the expanded relationship with GreenSky in boosting the firm’s price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SNV: